Literature DB >> 25413901

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.

Shin-Yeu Ong1, Hong Yen Ng2, Shilpa Surendran1, Yeh Ching Linn1, YunXin Chen1, Yeow Tee Goh1, Colin Diong1, Sathish Kumar Gopalakrishnan3.   

Abstract

Entities:  

Keywords:  bortezomib; bortezomib-cyclophosphamide-dexamethasone; bortezomib-thalidomide-dexamethasone; cyclophosphamide; multiple myeloma; thalidomide

Mesh：

Year:  2014        PMID： 25413901     DOI： 10.1111/bjh.13238

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Yan Xu; Shuhui Deng; Xuehan Mao; Gang An; Zengjun Li; Yafei Wang; Mariateresa Fulciniti; Matthew Ho; Jianhong Lin; Weiwei Sui; Wei Liu; Dehui Zou; Shuhua Yi; Wenyang Huang; Hong Liu; Rui Lv; Jian Li; Tingyu Wang; Chenxing Du; Nikhil C Munshi; Lugui Qiu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-15

2.  Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy.

Authors:  Yong Tang; Ye-Hua Yu; Yi-Yun Yao; Li-Fang Zou; Hong-Ju Dou; Lei Wang; Qi Zhu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-27       Impact factor: 0.900

3.  The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.

Authors:  Sanjay de Mel; Yunxin Chen; Sathish Kumar Gopalakrishnan; Melissa Ooi; Constance Teo; Daryl Tan; Min Li Claire Teo; Allison Cy Tso; Lian King Lee; Chandramouli Nagarajan; Yeow Tee Goh; Wee Joo Chng
Journal:  Singapore Med J       Date:  2016-09-09       Impact factor: 1.858

4.  [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma].

Authors:  Y Gu; Y H Yuan; Q L Shi; X Y Qu; J Xu; R Guo; J D Xu; J Y Li; L J Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

5.  Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data.

Authors:  Jingsong He; Donghua He; Xiaoyan Han; Gaofeng Zheng; Guoqing Wei; Yi Zhao; Yang Yang; Wenjun Wu; Jiaping Fu; Lihong Shou; Hongwei Kong; He Huang; Zhen Cai
Journal:  Front Pharmacol       Date:  2020-12-11       Impact factor: 5.810

6.  Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in China.

Authors:  Xiaoyan Han; Chunxiang Jin; Gaofeng Zheng; Donghua He; Yi Zhao; Yi Li; Wenjun Wu; Weiyan Zheng; Guoqing Wei; Enfan Zhang; He Huang; Jingsong He; Zhen Cai
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.